A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

NCT05062577 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Due to corporate strategic considerations

Conditions

Opioid Use Disorder

Interventions

DRUG: ASP8062
DRUG: Placebo ASP8062
DRUG: buprenorphine/naloxone

Sponsor

Astellas Pharma Global Development, Inc.